Funding Information

The Centre finances the following assisted reproduction activities:

1. Controlled ovarian (hyper) stimulation (COHS) with one or more of the following medicinal products (by group):
   
   • Gonadoliberin analogues (agonists or antagonists)
   • Gonadotropic hormones (urinary or recombinant)
   • Other (for luteal maintenance) — steroids and/or chorionic gonadotropin
2. Control of the stimulation process by:
   
   • Documented ultrasound examinations;
   • Hormonal studies;
3. ART methods (in vitro methodologies):
   
   • Follicular puncture under ultrasound control;
   • Classic in vitro fertilization;
   • Fertilization by the so-called ICCI;
   • (as amended — DV, No. 4 of 2018, in force from 01.01.2018) transfer of fresh embryos;
   • (amendment — DV, No. 4 of 2018, in force as of 01.01.2018) cryopreservation of pre-implantation embryos or ova (in the cases referred to in Art. 26, para. 1, item 6);
   • (new — DV, No. 4 of 2018, in force from 01.01.2018) transfer of thawed embryos,
     which have been cryopreserved by means of the centre — the necessary echographic examinations, thawing of embryos, culturing as needed and embryo transfer;
   • (new — DV, issue 4 of 2018, in force from 01.01.2018) assisted reproduction of the spontaneous cycle — the necessary echographic examinations, 4 follicular punctures under echographic control, fertilization, freezing and thawing of embryos, cultivation if necessary and the required number of embryo transplants sphere/s.
   • Medicinal products financed with funds from the center should be included in the Positive Drug List and are provided in accordance with Art. 207, para. 1, item 5a of the Law on Medicinal Products in Human Medicine.

The Center finances the indicated in persons with infertility, treatable primarily by ART methods and more specifically by in vitro fertilization in the presence of the following indications:

1. Female tubal sterility (ICD-X: N97.1)
   
   • absence of fallopian tubes bilaterally (surgically removed);
     
   • Unilateral absence with contralateral obstruction or stenosis;
     
   • Bilateral obstruction of the fallopian tubes (incl. after sterilization);
     
   • Unilateral obstruction with contralateral stenosis;
     
   • Bilateral interstitial or isthmic stenosis;
     
   • Condition after tubal plasty at least 12 months after plasty, provided that no intrauterine pregnancy has occurred;
     
   • (as amended — DV, No. 58 of 2011) proven severe endometriosis (III and IV AFS classes), as well as milder, but affecting the integrity of the fallopian tubes;
2. (as amended, issue 88 of 2023) male factor related sterility (ICD-X: N97.4):
   ‍
   • Azoospermia, in histological data on the presence of spermatogenesis;
   • Oligo- and/or astheno- and/or teratozoospermia requiring ART by IVF or ICSI with at least two of the following parameters:
     
     • ejaculate volume < 1.3 ml;
     • total sperm count in the ejaculate < 35 million;
       
     • sperm with good motility < 29% (grade 1 — 2);
       
     • spermatozoa with good morphology < 3,9%;
     • presence of sperm antibodies in the man and/or woman;
3. Sterility in a woman associated with a lack of ovulation due to LUFS.
   
4. Infertility with etiology not clarified by conventional diagnostic methods.
   
5. (new — DV, No. 4 of 2018, in force as of 01.01.2018) proven monogenic genetic disease or proven balanced chromosomal mutation in at least one of the partners.
   
6. (new — DV, No. 4 of 2018, in force as of 01.01.2018) proven oncological disease in a woman.

The Centre shall not provide funding beyond paragraphs 1 and 2, including:

1. Initial research to reach a diagnosis and decision on ART by in vitro fertilization;
2. The examinations required as a minimum according to the Assisted Reproduction Activities Ordinance as follows:
   
   • Microbiological
   • Sperm analysis
   • For transmissible infections
   • Blood group affiliation and rhesus factor
     
   • Hormonal — before COHS
     
   • On blood counts, biochemistry and hemostasis
   • Other specific studies (genetic, immunological, etc.)
3. Studies outside those specified in the Assisted Reproduction Activities Ordinance, regardless of the time of their performance.
   
4. Induction of ovulation and/or COHS with clomiphene citrate, etc. SERUM
5. Inseminations by the partner or donor
6. Embryoreduction
7. Pre-implantation genetic diagnosis or screening (PGD/PGS)
8. In vitro maturation (IVM)
9. Oocyte donation
10. Embryodonation
11. GIFT, ZIFT and similar
12. Testicular and/or epididymal biopsy (TEse, PESA, MESA).